NANOBIOTIX (EPA:NANO) | WebDisclosure

Basculer en Français

10669	Companies
227372	Keywords
155736	Articles
120389	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 02/12/2025 at 22:15, 1 year 4 months ago

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Communiqué mensuel de Nanobiotix sur les droits de vote et actions. Informations financières conformes à la règlementation des marchés financiers. Nanobiotix, société de biotechnologie, cotée à Euronext Paris et Nasdaq, développe des traitements innovants

Euronext Paris Biotechnologie Nasdaq NANOBIOTIX Traitements Innovants
PRESS RELEASE

published on 02/12/2025 at 22:15, 1 year 4 months ago

Voting Rights and Shares Capital of the Company
Nanobiotix announces voting rights and shares capital details. Company listed on Euronext Paris and Nasdaq. Focus on disruptive therapeutic approaches

Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF

published on 12/17/2024 at 22:20, 1 year 6 months ago

NANOBIOTIX Prépare son Événement Virtuel Révolutionnaire

Cancer NANOBIOTIX Technologie Nanothérapeutique Curadigm Médicaments Intraveineux
BRIEF

published on 12/17/2024 at 22:20, 1 year 6 months ago

NANOBIOTIX Prepares its Revolutionary Virtual Event

Cancer NANOBIOTIX Curadigm Nanotherapeutic Technology Intravenous Medications
PRESS RELEASE

published on 12/17/2024 at 22:15, 1 year 6 months ago

NANOBIOTIX présentera sa vision pour révolutionner la conception et le développement de médicaments à travers sa prochaine plateforme nanothérapeutique le 19 décembre 2024
Nanobiotix présente sa plateforme nanothérapeutique lors d'un événement virtuel le 19/12 à 15h00 CET / 9h00 ET pour améliorer les traitements pour les patients atteints de cancer

Innovation Cancer Événement Virtuel NANOBIOTIX Nanothérapeutique
PRESS RELEASE

published on 12/17/2024 at 22:15, 1 year 6 months ago

NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
Nanobiotix announces virtual event 'Accelerating the Future of Nanotherapeutics' on December 19, 2024, showcasing Curadigm Nanoprimer Platform for drug development

Virtual Event NANOBIOTIX Curadigm Nanotherapeutics Nanoprimer
BRIEF

published on 12/09/2024 at 22:20, 1 year 6 months ago

Nanobiotix conclut avec succès une étude de phase 1 sur le cancer du pancréas

FDA Étude De Phase 1 Cancer Du Pancréas Chimiothérapie Radiothérapie
BRIEF

published on 12/09/2024 at 22:20, 1 year 6 months ago

Nanobiotix successfully completes phase 1 study in pancreatic cancer

FDA Pancreatic Cancer Chemotherapy Phase 1 Study Radiotherapy
PRESS RELEASE

published on 12/09/2024 at 22:15, 1 year 6 months ago

NANOBIOTIX annonce l’achèvement de l’étude de phase 1 avec NBTXR3 (JNJ-1900) dans le cancer du pancréas
Nanobiotix annonce l'achèvement de l'étude de Phase 1 avec NBTXR3 dans le cancer du pancréas, avec des résultats encourageants. Un essai randomisé est prévu. Plus d'informations sur www.nanobiotix.com

Étude De Phase 1 Cancer Du Pancréas NANOBIOTIX NBTXR3 Essai Randomisé
PRESS RELEASE

published on 12/09/2024 at 22:15, 1 year 6 months ago

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
Nanobiotix completes Phase 1 study of NBTXR3 in pancreatic cancer, showing promising outcomes & safety profile. FDA approves new trial. Full data to be shared in 2025

FDA Approval Pancreatic Cancer NANOBIOTIX NBTXR3 Phase 1 Study

Accesswire

Published on 07/01/2026 at 03:15, 6 hours 7 minutes ago

GLG Life Tech Corporation Announces 2026 AGM Voting Results
Published on 07/01/2026 at 01:00, 8 hours 22 minutes ago

Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing
Published on 07/01/2026 at 00:00, 9 hours 22 minutes ago

Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010
Published on 06/30/2026 at 23:01, 10 hours 21 minutes ago

NextSource Materials Provides Clarification on a Prior News Release
Published on 06/30/2026 at 22:30, 10 hours 52 minutes ago

International Battery Metals Announces Change of Auditor

View all ACCESSWIRE

EQS Group

Published on 07/01/2026 at 09:15, 7 minutes ago

Breda University: disabled air travellers still face barriers despite existing regulations
Published on 07/01/2026 at 09:10, 12 minutes ago

Chow Tai Fook Presents "Chinese Couture" High Jewellery Exhibition in Shanghai
Published on 07/01/2026 at 09:01, 21 minutes ago

Nemetschek Group Successfully Completes Acquisition of HCSS
Published on 07/01/2026 at 09:00, 22 minutes ago

Original-Research: OHB SE (von NuWays AG): BUY
Published on 07/01/2026 at 09:00, 22 minutes ago

Giotto.ai ouvre gratuitement l'accès à son système d'IA via le cloud

Les Echos

Published on 07/01/2026 at 08:45, 37 minutes ago

Air Liquide investit plus de 170 millions USD aux États-Unis pour soutenir l'ambition de SK hynix de bâtir un écosystème mondial de mémoires pour l’IA
Published on 07/01/2026 at 08:45, 37 minutes ago

Air Liquide invests over 170M USD in the U.S. to support SK hynix’s ambition to build a global AI memory ecosystem
Published on 07/01/2026 at 07:00, 2 hours 22 minutes ago

BIOPHYTIS REPORTS ITS PROVISIONAL FINANCIAL RESULTS AND PROVIDES ITS STRATEGIC OUTLOOK
Published on 07/01/2026 at 07:00, 2 hours 22 minutes ago

Biophytis communique ses résultats financiers provisoires et partage ses perspectives stratégiques
Published on 06/30/2026 at 20:52, 12 hours 29 minutes ago

Number of shares and voting rights - May 2026 (In French only)

View all LES ECHOS COMFI WIRE